Aim-To investigate the fate of Streptococcus pneumoniae C-polysaccharide antigen in serum in patients with S pneumoniae bacteraemia. Method-In vitro dissociation experiments were performed to demonstrate that C-polysaccharide was masked by ligands in normal and acute phase serum. Serum samples from 22 patients with S pneumoniae bacteraemia were treated to dissociate immune complexes and then tested for C-polysaccharide by enzyme linked inimunosorbent assay (ELISA). Results-C-polysaccharide antigen was masked in normal and acute phase serum but could be released by EDTA treatment and detected by ELISA. Antigen was found in six patients ranging in concentration from 2-5 to 200 nglml. Patients with detectable antigen were more likely to die than those in whom antigen was not detected. Conclusion-This study demonstrates that C-polysaccharide antigen commonly circulates in patients with Spneumoniae bacteraemia but its presence is masked by ligands present in serum. (J7 Clin Pathol 1995;48:803-806) 
Streptococcus pneumoniae is the commonest bacterial cause of acute community acquired pneumonia.' Bacteraemia is an important lifethreatening complication of S pneumoniae induced pneumonia which still has approximately 30% mortality despite the availability of antibiotics to which this organism is usually sens- itive.'
Although the bacterial capsule is an essential determinant of pathogenicity,' it is not toxic to the host. Its main activity is to inhibit phagocytosis by preventing contact between the phagocyte surface and complement components deposited on the bacterial cell wall.' C-polysaccharide is the major cell wall polysaccharide antigen of S pneumoniae. Native Cpolysaccharide is a ribitol teichoic acid composed of a repeating oligosaccharide subunit made up of O-D-glu p-1-3-oa-acetoamido-trideoxygalactosamine p-1 -4-ca-D-GalNAc p-1-3-,B-D-GalNH2p-l-l'-ribitol-5-phosphate. 4 The immunodominant epitope is made up of the two phosphorylcholine residues attached to the oligosaccharide subunit. 4 The Spneumoniae lipoteichoic acid, known as the F antigen, has a similar polysaccharide structure and also contains phosphorylcholine.4
The importance of C-polysaccharide in the pathogenesis of inflammation in S pneumoniae infection is being increasingly recognised. Cpolysaccharide and F antigen activate the alternative complement pathway56 via the phosphorylcholine component. C-polysaccharide is the active cell wall component, as removal of teichoic acid from peptidoglycan diminishes complement activation by cell wall components. The plasma membrane is also a weak activator of the alternative pathway, and this activity resides in the lipoteichoic acid F antigen.' The components of the complement cascade generated by interaction with C-polysaccharide are thought to be crucial in the generation of an inflammatory reaction in the alveoli7 and the meninges.' Studies of inflammation in the rabbit model indicate that those fractions of killed S pneumoniae which contain teichoic acid polymers induce inflammation when injected into the cisterna magna.9 Organisms with high spontaneous loss of phosphorylcholine containing components induce a greater inflammatory response in the rabbit meninges.9
The fate of C-polysaccharide in the body is unknown. There is only a single report of serum C-polysaccharide antigen in a splenectomised patient with fulminant bacteraemia.'0 There is also a single report of C-polysaccharide antigen being found in urine." We postulated that Cpolysaccharide antigen was present in serum but masked by ligands such as anti-phosphorylcholine antibody and C-reactive protein (CRP). We have now shown that this is the case experimentally and in a series of patients with S pneumoniae bacteraemia. C-polysaccharide antigen (ng/ml) 
Results
Detection of dilutions of C-polysaccharide antigen in TBSTC buffer, normal serum and acute phase plasma are illustrated in fig 1A. It shows that C-polysaccharide antigen cannot be detected in acute phase when it is added to normal serum. The results of assays following immune complex dissociation are illustrated in fig 1B. These data suggest that the standard antigen dilution curve can be reconstituted by treatment of acute phase and normal serum with EDTA.
Serum samples from 22 patients (13 males and nine females; mean age 63 years, median 69 years, range seven months to 92 years) with acute S pneumoniae bacteraemia were examined. Pneumonia was the main condition in 17 cases and conformed to a lobar pattern in eight. In four patients bacteraemia was a complication of meningitis and in one bacteraemia was present without evidence of localised infection. A predisposition to infection was found in six patients with chronic obstructive airways disease, in three following acute myocardial infarction and congestive cardiac failure, and in one with immunosuppression due to azothioprim and steroid therapy.
There was a fatal outcome in five patients, directly related to S pneumoniae infection in three. A single fatal case was associated with acute pancreatitis and Proteus sp. bacteraemia, and in another death occurred suddenly 12 days after acute myocardial infarction.
C-polysaccharide antigen was found in serum from six of the 22 patients with S pneumoniae bacteraemia in concentrations ranging from 2-5 to >200 ng/ml. Of these six patients,
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Serum C-polysaccharide in S pneumoniae bacteraemia None of the samples from the 36 control patients had a positive result in the C-polysaccharide antigen capture assay. This suggests that C-polysaccharide antigen detection in serum has a sensitivity of 27% and a specificity of 100%.
Discussion
The fate of S pneumoniae capsular antigens has been studied but the mechanism by which the body breaks down microbial polysaccharide antigens is obscure. During in vitro and in vivo growth, S pneumoniae soluble and insoluble type specific capsular polysaccharide antigens are produced. Once solubilised, capsular antigens readily cross serous membranes and are excreted in the urine.'5 Capsular polysaccharide found in urine has a lower molecular weight than antigen found in the circulation. The electrophoretic mobility differs and double immunodiffusion shows only lines of partial identity with vaccine antigen.'6 It is suggested that in vivo degradation occurs with the effect that antigens of progressively lower molecular weights are excreted in the urine. It is presumed that the mass of capsular antigen generated during infection is slowly degraded and antigenuria may persist for several weeks. The fate of other polysaccharide antigens including Cpolysaccharide is not known. The results reported in fig 1 suggest that both normal human serum and acute phase plasma have sufficient binding capacity to inhibit the immunological detection of C-polysaccharide. The detection of C-polysaccharide is prevented by phosphorylcholine binding ligands and when serum is treated with EDTA the antigen is released and can be detected. This study confirms this also happens in vivo as C-polysaccharide antigen can be found in the serum of patients with S pneumoniae bacteraemia. The presence of C-polysaccharide in serum has only previously been reported in a premortem specimen of a splenectomised patient with fulminant bacteraemia'°where the quantity of antigen may have overcome the circulating ligand binding capacity. C-polysaccharide antigen has also been reported in urine samples from patients with bacteraemia but only when concentrated 50-fold."' The results reported here together with the report of C-polysaccharide in urine suggest that C-polysaccharide antigenaemia is a common event in severe S pneumoniae bacteraemia.'°11
In their seminal paper, Austrian and Gold'7 demonstrated the continuing high mortality associated with S pneumoniae bacteraemia stating "Some persons are at higher risk of death from pneumococcal infection which was not influenced by antimicrobial therapy in the first 48 hours following hospital admission". Patients with fulminant disease show profound hypocomplementaemia with consumption of the components of the alternative complement pathway. It has also been shown that in patients with complicated S pneumoniae infection alternative complement pathway factors were significantly depleted when compared with patients with uncomplicated infection. 18 In view of the importance of teichoic acid components in generating inflammation by activation of the alternative complement pathway the presence of C-polysaccharide antigenaemia demonstrated in our bacteraemic patients supports the idea that this antigen has an important role in the pathogenesis of this disease.
Demonstration of circulating C-polysaccharide may also explain the contradictory results of some protection studies using phosphorylcholine binding ligands. Rabbit polyclonal and mouse monoclonal antibodies directed against phosphorylcholine have been shown to protect mice from fatal challenge'9 and this has also been shown for CRP.20 One explanation for this protection was thought to be by enhancement of opsonisation. 8 Cpolysaccharide is situated deep within the capsule and is not available for opsonisation and therefore opsonisation experiments have indicated that antibodies directed against phosphorylcholine, in contrast to those directed against C-polysaccharide, do not promote phagocytosis for most S pneumoniae serotypes" and that the opsonising efficacy of serum can be correlated with levels of anti-capsular but not anti-phosphorylcholine antibody.2' It is possible that the mechanism of protection associated with phosphorylcholine binding ligands is due to its ability to bind free Cpolysaccharide and prevent overwhelming activation of the complement cascade.
In this study C-polysaccharide was detected in the serum of five of 20 patients with bacteraemic Spneumoniae infection. This is similar to the proportion of patients with Spneumoniae bacteriaemia in whom capsular polysaccharide can be detected.2221 C-polysaccharide antigen was found in only six of 22 patients with S pneumoniae bacteraemia although all ofthe control serum samples were negative for this antigen. As a diagnostic test, this is equivalent to a sensitivity of 27% and a specificity of 100%.
Although this is the first report of the use of C-polysaccharide antigen detection in serum by lysis of immune complexes it is clear that this method is specific but does not provide any further advantages to capsular antigen de-tection methods already reported.2223 Further studies are underway to determine the importance of C-polysaccharide antigen concentration with respect to outcome.
